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InﬂammationExcessive levels of the glycolysismetabolitemethylglyoxal (MG) elicit enhanced expression of adhesionmolecules
which foster leukocyte–endothelial cell interactions. The signaling mechanisms involved remain elusive. To ad-
dress this, we investigated the signal transduction of leukocyte- and endothelial-expressed phosphoinositide 3-
kinase (PI3K) effector kinases glycogen synthase kinase 3 (GSK3) and serum- and glucocorticoid-inducible kinase
1 (SGK1) in the regulation ofMG-elicited leukocyte recruitment. Using intravitalmicroscopy ofmouse cremasteric
microvasculature, we demonstrate that GSK3 inhibitors lithium and SB216763 mitigate MG-elicited leukocyte re-
cruitment and microvascular hyperpermeability. In SVEC4-10EE2 endothelial cells, but not in neutrophils, MG
transiently activates GSK3 by reducing inhibitory phospho-GSK3α/β (Ser21/9) which parallels decrease of
phospho-Akt at early time points (b30 min). At later time points (≥1 h), MG induces GSK3 deactivation which
is dissipated by siRNA silencing of SGK. MG treatment potentiates endothelial SGK1 mRNA, total SGK1,
phospho-SGK1 and phospho-NDRG1. The SGK1 inhibitor GSK650394 attenuates MG-elicited leukocyte recruit-
ment. Pharmacological inhibition or silencing endothelial GSK3 or SGK attenuates MG-triggered nuclear factor
(NF)-κB activity. Furthermore, silencing SGK blunts MG-triggered redox-sensitive phosphorylation of endothelial
transcription factor CREB. Inhibition of SGK1 or GSK3 mitigates the expression of endothelial adhesion molecules
P- and E-selectins and ICAM-1.Moreover, SGK1-dependent CREB activation participates inMG-elicited ICAM-1up-
regulation. We conclude that temporal activation of endothelial SGK1 and GSK3 is decisive in MG-elicited upreg-
ulation of transcription factors, adhesion molecule expression, and leukocyte-vascular endothelium interactions.
This novel signaling pathwaymay link excessiveMG levels in vivo to inﬂammation, thus, unraveling potential ther-
apeutic targets.protein; EE2 ECs, SVEC4-10EE2
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In diseases such as diabetes and renal failure, which are associated
with excessive levels of the glycolysis metabolite methylglyoxal (MG),
pathological vascular changes and impaired leukocyte–endothelial cell
interactions contribute to the pathophysiology of inﬂammatory sequelae
[1,2]. In addition to the widely documented cytotoxic effects of MG,various studies have reported the relative safety of its treatment in vivo
[3,4] including its anti-cancer [3,5–7], anti-microbial [8] and anxiolytic
effects [9]. MG modulates immune functions by stimulating macro-
phages [10], suppressing T-cell functions [11], triggering neutrophil apo-
ptosis [12] and inducing cytokine production [13]. Ramiﬁcations of
excessive levels of MG include increased expression of adhesion mole-
cules on leukocytes and endothelial cells which fosters redox-sensitive
leukocyte recruitment [12,14–16]. Putative signaling mechanisms that
regulate leukocyte–endothelial cell interactions associated with exces-
sive MG levels, however, remain elusive.
Phosphoinositide 3-kinases (PI3K) are crucial signal transducers
in leukocyte recruitment and microvascular leakage during inﬂam-
mation [17,18]. The glycogen synthase kinase GSK3 is a pleiotropic
serine/threonine kinase and critical downstream effector, in addition to
Akt, of PI3K signaling [19]. Both Akt and serum- and glucocorticoid-
inducible kinase 1 (SGK1) phosphorylate and inactivate GSK3 [20,21].
GSK3 regulates glucose homeostasis and is inhibited by the stimulation
of insulin receptors [19], thus playing a crucial role in energymetabolism.
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a positive or negative regulatory role [22]. GSK3was previously shown to
participate in leukocyte motility [23] and survival [24]. Interestingly, en-
dothelial GSK3 was reported to regulate E-selectin expression [25] and
vascular permeability [26], thus highlighting the signiﬁcance ofGSK3 sig-
naling in non-hematopoietic endothelial cells. The GSK3 inhibitors lithi-
um and SB216763 increase the inhibitory phosphorylation of GSK3 (Ser-
21/9) and have been widely used to study putative functions of GSK3
[27].
Similar to Akt, the ubiquitously expressed SGK1 is activated by PI3K
and phosphoinositide-dependent kinase-1 (PDK1) and is genomically
regulated by a wide array of stimuli [28] including hyperglycemia
[29]. In addition to its regulatory role in insulin secretion [30], SGK1
was previously shown to affect helper T-cell function [31], macrophage
polarization [32] and regulation of neutrophil apoptosis [33] alluding to
its role in immunity. Beyond the regulation of endothelial cell survival,
migration and vascular remodeling [34,35], the functions of endothelial-
expressed SGK1 are not well understood. Noticeably, SGK1 was shown
to activate nuclear factor-κB (NF-κB) [36] and cyclic AMP response
element-binding protein (CREB) [37], two transcription factors that are
important inmediating inﬂammatory responses. The small-molecular in-
hibitor GSK650394 formulated for in vivo use is known to potently sup-
press the enzymatic activity of SGK1 [38].
SGK1- and GSK3-dependent signaling, therefore, lies at the mecha-
nistic interface of both hyperglycemic pathophysiology and inﬂamma-
tion. In this study, using targeted gene silencing and pharmacological
inhibition, we elucidate the regulatory role of SGK1 and GSK3 signaling
on endothelial transcription factors and adhesion molecule expression,
and use intravital microscopy to unravel their role in MG-triggered
leukocyte–endothelial cell interactions in vivo.
2. Materials and methods
2.1. Mice and intravital microscopy
Male C57BL/6mice (Charles River, Saint-Constant, QC, Canada) aged
8–12wk-old were used in this study with the approval of animal proto-
cols from UCACS (# 20070028) at the University of Saskatchewan. Mice
were anesthetised using an i.p. injection of 10 mg/kg xylazine (Bayer,
Toronto, ON, Canada) and 200 mg/kg ketamine hydrochloride (Rogar,
Montreal, QC, Canada). The mouse cremaster muscle preparation was
used to study dynamic leukocyte–endothelial interactions in microvas-
culature as described [15,16,18]. Velocity of rolling leukocytes (μm/s),
and the number of adherent (cells/100-μm venule), and emigrated leu-
kocytes (cells/443 × 286 μm2 ﬁeld) were determined in the cremasteric
postcapillary venule (25–40 μm diameter) using video playback analy-
sis [15,16,18]. MG-triggered microvascular leakage was determined in
postcapillary venules of the cremaster muscle by intravital microscopy
measuring ﬂuorescence intensity of FITC-labeled BSA (25 mg/kg i.v.;
Sigma) inside and outside the vessel for calculating permeability index
as described [16]. Where indicated, MG (50 mg/kg or 100 μM; Sigma,
Oakville, ON, Canada), SB216763 (10 mg/kg or 20 μM; Sigma), lithium
(LiCl, 20 mg/kg; Sigma), BAY11-7082 (20 mg/kg; Sigma) or GSK650394
(50 mg/kg; Sigma) was administered by an intrascrotal injection or
superfusion of exposed cremaster muscle.
2.2. Cell culture and gene silencing
Murine microvascular SVEC4-10EE2 endothelial cell line cells (EE2
ECs; ATCC, Manassas, VA) were cultured as described earlier [39].
Where indicated, Tempol (300 μM; Sigma) and other pharmacological
modulators were added at speciﬁed concentrations. Targeted gene si-
lencing was accomplished by a 48-h transfection of EE2 ECs with
siRNA speciﬁcally targeting GSK3 (Cell Signaling), CREB (Cell Signaling)
or SGK (Santa Cruz) and with siRNA transfection medium and reagent
(Santa Cruz) as described previously [40]. The control cells weretransfected with negative control scrambled siRNA (Santa Cruz) having
no homology to any known RNA sequence.
2.3. Neutrophil isolation
Neutrophils from murine femurs and tibia were isolated using 3-
step Percoll (GE Healthcare, Uppsala, Sweden) gradient (72%, 64% and
52%) centrifugation at 1060 ×g for 30 min as described [39].
2.4. FACS analysis
Neutrophil Mac-1 expression was determined using ﬂuorescent anti-
Mac-1 antibody (Anti-mouse CD11b FITC; cloneM1/70; eBioscience) and
its respective isotype control (Rat IgG2bκ FITC; eBioscience) using a pre-
viously reported protocol [41].
2.5. Immunoblotting
Endothelial cells or cremaster tissue homogenates were lysed using
Phosphate Extraction Reagent (Novagen) or Nuclear Extraction Kit
(Cayman). Proteins were solubilized in Laemmli buffer and resolved
by 8–10% SDS-PAGE, and thereafter transferred to a nitrocellulose
membrane and immunoblotted as described [39]. Respective primary
(1:1000) and secondary antibodies were used to detect the proteins of
interest. The following antibodies were used in the present study:
CREB, NDRG1 and phospho-NDRG1-Thr346, GSK3 and phospho-GSK3-
Ser-21/9 (Cell Signaling); phospho-CREB and phospho-GSK3-Tyr-279/
216 (Millipore), Akt and phospho-Akt-Ser-473 (BD Pharmingen);
P-selectin (LifeSpan Biosciences); E-selectin, ICAM-1, and SGK1
(Abcam); β-actin, and phospo-SGK1-Thr-256 (Santa Cruz). Intensity
values for the proteins were normalized to β-actin.
2.6. Real-time PCR
RT-PCRwasperformed todetermine SGK1, ICAM-1 andβ-actinmRNA
expression as described previously [42]. Brieﬂy, RNA was isolated from
the cells using RNA isolation kit (Qiagen) and reverse-transcribed using
reverse transcription kit (Qiagen). RT-PCR was carried out by SYBR
green PCR kit (Qiagen) in an iCycler iQ apparatus (Bio-Rad, Hercules,
CA) with primers targeting SGK1 (QT02379685; Qiagen), ICAM-1
(QT00155078; Qiagen) and β-actin (QT00095242; Qiagen). All PCRs
were performed in triplicate and ran for 30 cycles at 95 °C for 30 s,
55 °C for 30 s, and 72 °C for 40 s.
2.7. Immunohistochemistry
Determination of adhesion molecule (E- and P-selectins and ICAM-1)
expression inwhole cremastermusclewas performedusing the samepri-
mary antibodies in immunoblotting and a previously described method
[15].
2.8. Analysis of NF-κB activity
After the indicated treatments, the whole cremaster muscle and cul-
tured EE2 ECswere subjected to nuclear extractionwith Nuclear Extrac-
tion Kit (Cayman). Equal amounts of nuclear extracts were loaded on a
96-well plate of the NF-κB p65 Transcription Factor Activation Assay Kit
(Abcam) and the manufacturer's instructions were followed.
2.9. Confocal imaging
EE2 ECs treated under different conditionswere ﬁxed using 4% para-
formaldehyde for 30 min, washed twice with PBS, blocked for 1 h with
5% goat serum (Abcam) and then incubated overnight at 4 °Cwith anti-
bodies against P-selectin (1:100; RB40.34; BD Pharmingen), E-selectin
(1:100, 9A9, a gift from Dr. Paul Kubes, University of Calgary, AB,
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cubated for 1 h with ﬂuorescence goat anti-rat antibody (Alexa Fluor
488; Invitrogen) and cells were washed, permeabilized with 0.1%
Triton X-100 and stainedwith Hoechst 33342 (Invitrogen). The slides
were mounted in ProLong® Gold Antifade Reagent (Invitrogen) and ob-
served under a laser scanning confocal microscope (Zeiss, ConfoCor2/
LSM510).
2.10. Statistical analysis
Data are shown as arithmetic mean ± SEM. Statistical analysis was
made using Student t test or ANOVAwith Tukey's post-hoc comparison
test. n denotes the number of different mice, different batches of
cremasteric tissues or endothelial cells studied in each group. Values
of p b 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Inhibition of GSK3 amelioratesMG-induced upregulation of endothelial
adhesion molecules, leukocyte recruitment and microvascular leakage
Firstly, we explored the effect of pharmacological GSK3 inhibitors
SB216763 and lithiumonMG-elicited leukocyte recruitment. The repre-
sentative intravital images of cremastericmicrovasculature are depicted
in Fig. 1A. Neither inhibitors themselves had any effect on leukocyteFig. 1. GSK3 inhibition ameliorates methylglyoxal-induced leukocyte recruitment, microvascul
adherent (white arrowheads) and emigrated (black arrowheads) leukocytes and (B) means ± S
igrated (cells/443× 286 μm2 ﬁeld) leukocytes inmouse cremasteric postcapillary venules determ
ofMGwith SB216763 (10 mg/kg) or lithium (20 mg/kg), both inhibitors administered 30min p
permeability index analysis of mouse cremasteric postcapillary venules showing the leakage of
superfusionwith SB216763 (20 μM) 30min prior to and during 1-hMG superfusion. (D) Repres
determined in mouse cremasteric endothelium 4 h after an intrascrotal injection of saline (Co
30 min prior to MG). Arrow indicates cremasteric venule. (E) Original Western blot and means
β-actin) in EE2 ECs in the absence (Control) or in the presence of MG without (+) or treated
the addition of MG). * (p b 0.05) from Control. # (p b 0.05) from MG alone.recruitment (data not shown). Fig. 1B shows increased numbers of
adherent and emigrated leukocytes after MG treatment compared to
saline treatment. Pretreatment with SB216763 or lithium signiﬁcantly
attenuatedMG-induced increases in adherent and emigrated cells. Treat-
ment with SB216763 or lithium signiﬁcantly restored MG-triggered re-
duction of leukocyte rolling velocity (Fig. 1B). To determine whether
pharmacological inhibition of GSK3 modulates microvascular permeabil-
ity during leukocyte recruitment, we measured ﬂuorescence changes of
FITC-conjugated albumin inside and outside cremasteric postcapillary ve-
nule. Permeability index analysis revealed that superfusion of MG on the
cremaster muscle increased microvascular permeability, an effect that
was signiﬁcantly inhibited by co-superfusion with SB216763 (Fig. 1C).
We further examinedwhether GSK3 inhibitionmodulated the expression
of endothelial adhesionmolecules P- and E-selectins and ICAM-1.Histo-
logical evaluation of the whole cremaster muscles revealed enhanced
expression of P- and E-selectins and ICAM-1 following treatment with
MG, an effect that was blunted by treatment with SB216763 (Fig. 1D).
These ﬁndings were further corroborated in murine EE2 ECs by si-
lencing GSK3 with siRNA or treatment with SB216763. To this end,
treatment of EE2 ECs with MG enhanced the expression of P- and
E-selectins and ICAM-1, an effect that was signiﬁcantly reduced by
SB216763 or GSK3 silencing but not by the negative control siRNA
(Fig. 1E). Moreover, silencing of endothelial GSK3 signiﬁcantly atten-
uated MG-triggered increase in endothelial ICAM-1 mRNA levels
(Supplementary Fig. 1).ar leakage and adhesion molecule upregulation. (A) Representative intravital images with
EM (n= 6) of leukocyte rolling velocity (μm/s), adherent (cells/100-μm venule) and em-
ined 4 h after an intrascrotal injection of saline (Control), MG (50 mg/kg) or co-treatment
rior toMG. (C) Representative ﬂuorescence intravital images andmeans±SEM (n=6) of
FITC-conjugated BSA before (0min) and 1 h after superfusion with MG (100 μM) alone or
entative immunohistochemistry showing the staining of P-selectin, E-selectin and ICAM-1
ntrol) or MG (50 mg/kg) or co-treatment of MG with SB216763 (10 mg/kg, intrascrotal,
± SEM (n= 4) showing the expression of P-selectin, E-selectin and ICAM-1 (relative to
with negative control siRNA, GSK3-targeted siRNA or SB216763 (20 μM, 30 min prior to
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In view of the modulatory effects of GSK3 inhibitors on MG-elicited
leukocyte recruitment, we studied the effect of MG on endothelial GSK3
downstream of PI3K signaling. To elucidate the activation of GSK3 by
MG in EE2 ECs, we analyzed time-dependent changes in inhibitory
(Ser-21/9) and activational (Tyr-279/216) GSK3α/β phosphorylation.
As a result, MG treatment of EE2 ECs elicited a signiﬁcant and transient
reduction in Ser-21/9 and increase in Tyr-279/216 GSK3α/β phosphor-
ylation at 15min,with both phosphorylation returning to thebasal level
at 30 min. After 1–4 h of MG treatment, Ser-21/9 phosphorylation was
signiﬁcantly increased and Tyr-279/216 phosphorylation was signiﬁ-
cantly reduced (Fig. 2A). Fig. 2B shows that exposure of MG-treated
EE2 ECs to SB216763, completely abrogated MG-induced GSK3 activa-
tion (reduced Ser-21/9 and increased Tyr-279/216 phosphorylation)
at 15 min without affecting the GSK3 deactivation at later time points
(1–4 h), indicative of the speciﬁcity of SB216763 in blocking GSK3Fig. 2.Methylglyoxal-sensitive modulation of endothelial Akt and GSK3 phosphorylation. Origi
GSK3α/β (Ser-21/9 and Tyr-279/216) in the absence (A) or in the presence (B) of 20 μM SB216
EE2 ECs (relative to β-actin). (C) OriginalWestern blot andmeans± SEM (n=4) showing tota
ECs (relative to β-actin). * (p b 0.05) from 0 min.activation. To further deﬁne the role of Akt, the upstream negative reg-
ulator of GSK3, in MG-triggered modulation of GSK3 activity, we deter-
mined Akt phosphorylation inMG-treated EE2 ECs. Exposure of EE2 ECs
to MG caused a transient and signiﬁcant reduction of phosphorylated
Akt (Ser-473) at 15 and 30 min, but not after 1–4 h MG exposure sug-
gesting the inhibitory effect of MG on Akt in PI3K signaling only at
early time points (Fig. 2C).
3.3. Neutrophil-expressed GSK3 does not participate in MG-induced
leukocyte recruitment
We then sought to elucidate the role of neutrophil-expressed GSK3
in leukocyte recruitment by examining the effect of MG on neutrophil
GSK3 activity. Treatment of neutrophils with MG for different time
points signiﬁcantly enhanced Tyr-279/216 and signiﬁcantly reduced
Ser-21/9 GSK3 phosphorylation, an effect reaching statistical signiﬁ-
cance at 30 min following MG exposure (Fig. 3A). To elucidate thenal Western blot and means ± SEM (n= 4) showing total GSK3α/β and phosphorylated
763 (added 30 min prior to MG treatment) determined inMG-treated (100 μM for 0–4 h)
l Akt and phosphorylated Akt (Ser-473) determined inMG-treated (100 μM for 0–4 h) EE2
Fig. 3. Effect of methylglyoxal on neutrophil-expressed GSK3. (A) Original Western blot and means ± SEM (n = 4) showing total GSK3α/β and phosphorylated GSK3α/β (Ser-21/9 and
Tyr-279/216) determined inMG-treated (100 μM for 0–4 h) bonemarrow neutrophils (relative to β-actin). * (p b 0.05) from 0min. (B)Means± SEM (n= 4) of Mac-1-dependent ﬂuo-
rescence inneutrophils incubatedwithout (Control) orwithMG (100 μMfor 1 h) in the absence (+)or in thepresence of SB216763 (20 μM)or Tempol (300 μM)added 30min prior to the
addition of MG. * (p b 0.05) from Control. # (p b 0.05) from MG alone.
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cological GSK3 inhibitionmodulates the hitherto known effect ofMGon
the expression of neutrophil β2 integrin Mac-1 [12], the decisive mole-
cule in leukocyte adhesion to endothelial cells [43]. Exposure of neutro-
phils to MG signiﬁcantly enhancedMac-1 expression, an effect that was
notmodiﬁed by SB216763 but was signiﬁcantly reduced by Tempol, the
scavenger of reactive oxygen species (ROS), suggesting that GSK3 in en-
dothelial cells but not in neutrophils is critical in MG-elicited leukocyte
recruitment (Fig. 3B).Fig. 4. Effect ofmethylglyoxal on endothelial SGK1 expression. (A)Mean± SEM of encoding SG
total SGK1 and phosphorylated SGK1 (Thr-256) determined in MG-treated (100 μM for 0–4 h)
protein expression inEE2 ECs. (D)OriginalWestern blot and arithmeticmeans±SEM(n=4) sh
silencing determined in MG-treated (100 μM for 0–4 h) EE2 ECs (relative to β-actin). * (p b 0.03.4. MG triggers endothelial SGK1 upregulation and temporally late SGK1-
dependent GSK3 inactivation
In addition to Akt, GSK3 is phosphorylated and inactivated by SGK1,
a PI3K effector kinase [20]. We, therefore, explored the role of SGK1 in
MG-induced leukocyte recruitment. First, we elucidated the transcrip-
tional upregulation of endothelial SGK1 triggered by MG. Fig. 4A shows
that endothelial SGK1mRNA levelswere signiﬁcantly increased following
MG treatment reaching statistical signiﬁcance after 1 hMG exposure. TheK1mRNA levels (n= 6) and (B) originalWestern blot andmeans± SEM (n=4) showing
EE2 ECs (relative to β-actin). (C) SGK-targeted siRNA silencing showing decreased SGK1
owing total GSK3α/β andphosphorylatedGSK3α/β (Ser-21/9 andTyr-279/216) after SGK
5) from 0 min.
2486 Y. Su et al. / Biochimica et Biophysica Acta 1843 (2014) 2481–2491levels of phosphorylated (Thr-256) and total endothelial SGK1 were
signiﬁcantly enhanced after 1 h and 2 h, respectively, following MG-
treatment of EE2 ECs (Fig. 4B). Furthermore, siRNA-targeted silencing of
endothelial SGK1 (Fig. 4C) did not signiﬁcantlymodify the acute and tran-
sient GSK3 activation (15 min) that is depicted in Fig. 2A, but abrogated
GSK3 deactivation after 1–4 h of MG treatment (Figs. 2A and 4D) indicat-
ing that SGK1 is not involved in early GSK3 activation but is a crucial up-
stream molecule in endothelial GSK3 deactivation at 1–4 h of MG
treatment.
3.5. Endothelial but not neutrophil SGK1 contributes to MG-induced
leukocyte recruitment
Further experiments addressed the effect of SGK1 inhibition onMG-
elicited leukocyte recruitment in vivo. Intravital microscopy analysis of
mouse cremasteric microvasculature in Fig. 5A revealed that SGK1Fig. 5. Participation of SGK1 in methylglyoxal-induced leukocyte recruitment. (A) Means ± SE
gration (cells/443 × 286 μm2 ﬁeld) determined 4 h after an intrascrotal injection of saline (Co
prior to MG). (B) Original Western blot and means ± SEM (n = 4) showing total SGK1 and
actin) 4 h after an intrascrotal injection of saline (Control) or MG (50 mg/kg). (C) Original We
(Thr-346) determined in whole cremaster muscle (relative to β-actin) at 4 h after an intras
GSK650394 (50 mg/kg, 30 min prior to MG). * (p b 0.05) from Control. # (p b 0.05) fromMG a
phorylated SGK1 (Thr-256) determined inMG-treated (100 μMfor 0–4 h) neutrophils (relative
P-selectin, E-selectin and ICAM-1 determined in whole cremaster muscle (relative to β-actin)
(50 mg/kg, 30 min prior to MG). * (p b 0.05) from Control. # (p b 0.05) from MG alone. (F) R
in EE2 ECs in the absence (Control) or in the presence of MG (100 μM, 4 h) alone (+) or co-tr
(20 μM, 30 min prior to MG).inhibitor GSK650394 signiﬁcantly reduced the number of adherent and
emigrated leukocytes triggeredbyMG treatment. Leukocyte rolling veloc-
ity tended to be higher in mice treated with both MG and GSK650394
compared tomice treatedwithMGalone, an effect not reaching statistical
signiﬁcance (Fig. 5A).MG treatment presented a substantial upregulation
of total and phosphorylated SGK1 in whole cremaster muscle (Fig. 5B),
thus, corroborating enhanced abundance of total and phosphorylated
SGK1 observed in vitro (Fig. 4B). Furthermore, the speciﬁcity and efﬁca-
cy of GSK650394 was determined by the phosphorylation of N-myc
downstream-regulated gene 1 (NDRG1), a speciﬁc target of SGK1 [44,
45].MG treatment enhancedNDRG1phosphorylation inwhole cremaster
muscle, an effect that was signiﬁcantly blunted by GSK650394 (Fig. 5C)
suggesting that GSK650394 speciﬁcally targets SGK1 in our model sys-
tem. We further observed that in neutrophils, MG exposure for different
durations had no appreciable changes in total or phosphorylated SGK1
(Fig. 5D), suggesting that SGK1 expressed in endothelial cells, but not inM (n= 6) of leukocyte rolling velocity (μm/s), adhesion (cells/100-μm venule) and emi-
ntrol) or MG (50 mg/kg) with or without treatment with GSK650394 (50 mg/kg, 30 min
phosphorylated SGK1 (Thr-256) determined in whole cremaster muscle (relative to β-
stern blot and means ± SEM (n = 4) showing total NDRG1 and phosphorylated NDRG1
crotal injection of saline (Control), or MG (50 mg/kg) with or without treatment with
lone. (D) Original Western blot and means± SEM (n= 4) showing total SGK1 and phos-
toβ-actin). (E)OriginalWestern blot andmeans±SEM (n=4) showing the expression of
in the absence (Control) or MG (50 mg/kg) with or without treatment with GSK650394
epresentative confocal micrographs of P-selectin, E-selectin and ICAM-1 immunostaining
eatment with negative control siRNA, SGK-targeted siRNA or SGK1 inhibitor GSK650394
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the underlying mechanisms of SGK1-sensitive leukocyte recruitment,
expression of endothelial adhesion molecules was determined in whole
cremaster muscle using immunoblotting and visualized in EE2 ECs
using confocal imaging. As depicted in Fig. 5E and F, exposure to MG
enhanced the expression of P- and E-selectins and ICAM-1 in whole
cremaster muscle and in EE2 ECs respectively, an effect abrogated after
SGK knockdown or GSK650394 treatment. Furthermore, SGK silencing
signiﬁcantly attenuated MG-triggered increase in endothelial ICAM-1
mRNA levels (Supplementary Fig. 1).
3.6. MG induces GSK3- and SGK1-dependent activation of NF-κB
Expression of endothelial adhesion molecules is effectively accom-
plished by activation of transcription factors. Using GSK3- or SGK-
targeted siRNA silencing, we examined dynamic changes of NF-κB acti-
vation in MG-treated EE2 ECs and whole cremaster muscle. Silencing
GSK3 or SGK signiﬁcantly reduced NF-κB activity in silenced versus
non-silenced MG-treated EE2 ECs, an effect reaching statistical signiﬁ-
cance at 15min (for GSK3 silencing) and 1 h (for SGK silencing) respec-
tively (Fig. 6A). To substantiate these data in vivo, we analyzed NF-κB
activity in whole cremaster muscle. Signiﬁcantly increased NF-κB activ-
itywas detected inMG-treated but not in saline-treated cremastermus-
cles. Pretreatment with SB216763, GSK650394 or the NF-κB inhibitor
BAY11-7082 signiﬁcantly attenuated MG-induced NF-κB activation
(Fig. 6B). These observations indicate that both GSK3 and SGK are sen-
sitive toMG and decisive in the regulation of MG-triggered NF-κB activ-
ity in endothelial cells, albeit at different time points.
3.7. MG-elicited redox-sensitive activation of endothelial CREB transcription
factor is regulated by SGK1
We further characterized the transcriptional regulation of endothe-
lial adhesionmolecule expression fostered by SGK1 by evaluating endo-
thelial CREB expression and phosphorylation in nucleus after exposure
of EE2 ECs to MG. As shown in Fig. 7A, the CREB phosphorylation and
total CREB expression were signiﬁcantly increased on exposure to MG,
an effect reaching statistical signiﬁcance at 1 h (phospho-CREB) and 2 h
(total CREB) respectively. Silencing SGK in EE2 ECs completely abolished
the increased total- and phospho-CREB expression induced by MG
(Fig. 7A). Silencing CREB (Fig. 7B) signiﬁcantly attenuated MG-triggered
ICAM-1 expression, but not the expression of P- and E-selectins
(Fig. 7C), suggesting that transcriptional regulation by SGK1-dependent
CREB is endothelial adhesion molecule-speciﬁc. We also tested whether
ROS was involved in MG-triggered CREB activation. As shown in Fig. 7D,
upregulation of total- and phospho-CREB in EE2 ECs triggered by MGFig. 6. SGK1 andGSK3 orchestratemethylglyoxal-induced endothelial NF-κB activation. (A)Mea
0–4 h) in the absence (MG) or in the presence of prior treatment with negative control siRNA
(B) Means ± SEM (n = 3) of relative NF-κB activity determined 4 h after an intrascrotal injecti
GSK650394 (50 mg/kg) or BAY11-7082 (20 mg/kg), the inhibitors being administered 30 min prwas signiﬁcantly blunted by the treatment with the antioxidant Tempol
indicating that CREB activation elicited by MG is ROS-dependent. To cor-
roborate our in vitroﬁndings, we further examined the expression of total
and phosphorylated CREB in the whole cremaster muscle. As shown in
Fig. 7E, MG-elicited upregulation of total- and phospho-CREB in whole
cremaster muscle was signiﬁcantly mitigated by treatment with
GSK650394 or Tempol.
4. Discussion
Endothelial adhesion molecules on the vascular lining are requi-
site elements during leukocyte recruitment at the site of inﬂamma-
tion. The present study unravels signaling mechanisms by which
endothelial-expressed GSK3 and SGK1 orchestrate rolling, adhesion
and transendothelial migration of leukocytes. By utilizing a previously
established mouse model simulating diabetes-associated inﬂammation
[15,16], we elucidate the hitherto unknown role of endothelial PI3K sig-
naling effectors SGK1 and GSK3 in MG-induced leukocyte–endothelial
cell interactions. In this study,we demonstrate the temporal endothelial
SGK1 and GSK3 signalingmechanism inMG-induced leukocyte recruit-
ment (depicted in Fig. 8). Excessive MG triggers Akt-dependent tran-
sient GSK3 activation in endothelial cells, which is responsible for NF-
κB activation at early time-points. After 1 h, the GSK3 activity decreases
due to the activation of SGK1 and the activated SGK1maintains the cru-
cial NF-κB activity at later time-points. This temporal activation of GSK3
and SGK1 is pivotal for endothelial adhesion molecules P- and E-
selectins and ICAM-1expression and consequently MG-induced leuko-
cyte recruitment in vivo. The activation of SGK1 is also responsible for
CREB activation, which regulates the expression of ICAM-1. MG acti-
vates GSK3 in neutrophils only after 30 min treatment, an effect, how-
ever, not responsible for Mac-1 expression. Both GSK3 and SGK1 in
neutrophils are not involved in MG-elicited leukocyte recruitment.
The physiological relevance of MG concentrations used in this study is
based on previous reports [46,47]. It has recently been shown that a
single administration of 50 mg/kg MG (intrascrotally for 4 h) yielded
concentrations of MG at approximately 1.7 μM and 3.9 nmol/mg pro-
tein in plasma and tissue respectively [15]. The concentration ofMGde-
tected in cremaster tissue is comparable to that detected in other organs
[48,49].
Here, we demonstrate that MG-triggered GSK3 activation in endo-
thelial cells, but not in neutrophils, is acute and transient and parallels
decreased phosphorylation of the upstream kinase Akt. The inhibitory
effect of MG on PI3K signaling and subsequent activation of GSK3 was
previously reported in pancreatic β-cells [50]. Similarly, MG was shown
to foster platelet aggregation by attenuation of Akt phosphorylation
[51]. Consistent with our ﬁndings in endothelial cells, short exposure ofns±SEM(n=4) of relativeNF-κB activity determined inMG-treated EE2 ECs (100 μMfor
, GSK3-targeted siRNA or SGK1-targeted siRNA. * (p b 0.05) from negative Control siRNA.
on of saline (Control), MG (50 mg/kg) or co-treatment of MG with SB216763 (10 mg/kg),
ior to MG. * (p b 0.05) from Control. # (p b 0.05) fromMG alone.
Fig. 7. Activation of CREB by methylglyoxal. (A) Original Western blot and means ± SEM (n = 4) showing total CREB and phosphorylated CREB (Ser-133) determined in MG-treated
(100 μM for 0–4 h) EE2 ECs and in MG-treated SGK-silenced EE2 ECs (relative to β-actin). * (p b 0.05) from 0 min. # (p b 0.05) from absence of SGK silencing. (B) CREB-targeted
siRNA silencing showing decreased CREB protein expression in EE2 ECs. (C) Original Western blot and means± SEM (n= 4) showing P-selectin, E-selectin and ICAM-1 expression (rel-
ative to β-actin) in EE2 ECs in the absence (Control) or in the presence of MG (100 μM, 4 h) without or with CREB silencing. * (p b 0.05) from Control. # (p b 0.05) from absence of CREB
silencing. (D) Original Western blot and means ± SEM (n = 4) showing total CREB and phosphorylated CREB (Ser-133) expression determined in EE2 ECs (relative to β-actin) in the
absence (Control) or in the presence of MG (100 μM, 4 h) without (MG) or with Tempol (300 μM, 30 min prior to MG). * (p b 0.05) from Control. # (p b 0.05) from MG alone.
(E) OriginalWestern blot and means± SEM (n= 4) showing total CREB and phosphorylated CREB (Ser-133) expression inwhole cremastermuscle determined 4 h after an intrascrotal
injection of saline (Control), MG (50 mg/kg) or co-treatment of MGwith GSK650394 (50 mg/kg) or Tempol (50 mg/kg), both agents administered 30min prior to MG. * (p b 0.05) from
Control. # (p b 0.05) from MG alone.
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and suggestive of the cell-speciﬁc effects of MG, Akt phosphorylation in
adipocytes [53] and vascular smooth muscle cells [54] was increased
after treatment with MG. Similar to MG treatment, transient activation
of GSK3 in endothelial cells was previously observed after treatment
with either thrombin or TNFα [55]. Our results also show that following
prolonged exposure to MG, inhibitory phosphorylation of endothelial
GSK3 was increased. Intriguingly, GSK3 activation in neutrophils, unlike
endothelial cells, is enhanced after prolonged exposure to MG.
Our results show that, with transient decrease in inhibitory phos-
phorylation, GSK3 acquires a proinﬂammatory activity in the context
of MG-induced endothelial activation for leukocyte recruitment which
is ameliorated by pharmacological GSK3 inhibition. Paradoxically, we ob-
served that inhibition of SGK1 similarly mitigates leukocyte recruitmentin vivo given that SGK1 is known to inactivate GSK3. Clearly, endothelial
SGK1 is genomically upregulated by exposure to MG and our in vitro re-
sults show that at later time points (>1 h), both total and phospho-
SGK1 levels are increased in contrast to the acute and transient activation
of GSK3. From our in vitro results, it is apparent that SGK1 and GSK3 sig-
naling in endothelial cells is temporal with Akt-paralleled GSK3 signaling
being decisive at early time points (15 min). At later time points SGK1 si-
lencing virtually abrogated MG-induced phosphorylation of endothelial
GSK3 (Ser-21/9). However, biological ramiﬁcation of this effect on GSK3
is unknown. Furthermore, SGK silencing blunts NF-κB activity at later
time points (>1 h) in contrast to GSK3 silencingwhich curtails NF-κB ac-
tivation at early time points. It is, therefore, tempting to speculate that at
later time points SGK1 directly mediates NF-κB activation independently
of its effect on GSK3.
Fig. 8. Scheme of methylglyoxal-elicited endothelial SGK1/GSK3 signaling.
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unknown. Here we unravel that MG treatment potentiates SGK1 tran-
script levels in endothelial cells. Previously, NADPH oxidases were
shown to be critically involved in the upregulation of SGK1 [36]. MG-
induced endothelial SGK1 upregulation is presumably redox-sensitive
because MG triggers ROS production which contributes to leukocyte–
endothelial cell interactions [16,56]. Surprisingly, SGK1 was not upreg-
ulated in neutrophils exposed to MG in contrast to the effect on GSK3
activation. The role of leukocyte-expressed SGK1, however, is not
completely understood. The hematopoietic growth factor granulocyte-
macrophage colony-stimulating factor (GM-CSF) was recently shown
to augment SGK1 transcript and protein levels in neutrophils and the
SGK1 inhibitor GSK650394 reduced GM-CSF-induced neutrophil sur-
vival [57]. SGK1 was shown to be effective by regulating Orai1/STIM1
and, thus, inﬂuences Ca2+-dependent functions such as cell migration
[58]. Along this line, Orai1was shown to be decisive in neutrophil arrest
and migration [59]. From the present study, however, it is unclear
whether thesemechanisms are operative for SGK1-sensitivity in leuko-
cytes in MG-induced leukocyte–endothelial cell interactions.
Previous observations demonstrated that MG induces NF-κB-
dependent upregulation of endothelial adhesionmolecules [15].We ob-
served that targeted gene silencing or pharmacological inhibition of ei-
ther GSK3 or SGK1 blunted the expression of endothelial adhesion
molecules elicited byMG. It is documented that GSK3 inhibition curtails
endothelial E-selectin [25], VCAM-1 [55], P-selectin and ICAM-1 expres-
sion [60,61]. Mounting evidence suggests that GSK3 is an essential ele-
ment for NF-κB activation [55,62,63]. Accordingly, our results showed
that knockdown of GSK3 gene dramatically reduced both activation of
NF-κB and expression of endothelial adhesion molecules, substanti-
ating the in vivo effects of GSK3 inhibitors on MG-induced leukocyte
recruitment.
Our study is the ﬁrst to demonstrate the modulatory role of SGK1 in
leukocyte recruitment in vivo by regulating the expression of endotheli-
al adhesionmolecules. SGK1was previously reported tomediateNF-κB-
dependent ICAM-1 expression in mesangial cells [64]. In accordance
with our results, knockdown of SGK1 gene was previously shown
to attenuate NF-κB activation in renal collecting duct cells [65].
SGK1 phosphorylates and activates NDRG1, a mechanism associated
with degradation of NF-κB inhibitory proteins [35]. We demonstrate
in this study that upon stimulation with MG, endothelial CREB is
phosphorylated in an SGK1-dependent manner. Upon stimulationwith glucocorticoids, the SGK kinases were shown to physically associ-
atewith CREB [37]. Recently, CREBwas reported to be essential in endo-
thelial ICAM-1 [66,67] VE-cadherin [68] and VCAM-1 upregulation [66].
Our data show that MG-triggered upregulation of endothelial ICAM-1,
but not P- and E-selectins, was at least partially mediated by CREB. Ad-
ditionally, CREB phosphorylation was documented to be ROS-sensitive
[69], a decisive mechanism in MG-elicited leukocyte–endothelial in-
teractions [16]. This mechanism is validated in our present study by
the inhibitory effect of the antioxidant Tempol on MG-triggered CREB
phosphorylation.
In summary, we provide biological evidence that temporal Akt-
dependent GSK3 activity and SGK1 signaling in endothelial cells are piv-
otal inMG-elicited up-regulation of transcription factors, adhesionmol-
ecule expression, and leukocyte interactionswith the activated vascular
endothelium. Pharmacologically targeting GSK3 or SGK1 alleviates
acute inﬂammation induced by MG, thus, unraveling potential thera-
peutic targets in inﬂammation associated with excessive MG levels.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.06.018.
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